Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Irritable Bowel Syndrome

Free Subscription 02.03.2026 1 Acta Gastroenterol Belg 1 bioRxiv 1 BMC Gastroenterol 1 Euroasian J Hepatogastroenterol 1 Foods 1 Front Immunol 1 Front Med (Lausanne) 1 Fundam Clin Pharmacol 1 Int Immunopharmacol 1 Int J Dermatol 1 J Biomater Sci Polym Ed 1 J Gastroenterol Hepatol 1 J Pediatr Gastroenterol Nutr 1 J Tradit Chin Med 1 Mol Neurobiol 3 Nutrients 1 Pharmaceutics 1 Pharmacol Rep 1 Psychother Psychosom 1 RSC Adv 1 Therap Adv Gastroenterol 1 Viruses 1 Zhen Ci Yan Jiu

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Gastroenterol Belg

1. ARGYRIOU K, Manolakis A, Tsakiridou E, Christodoulou D, et al
   Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle.
   Acta Gastroenterol Belg. 2026;89:65-77.
   PubMed         Abstract available
   
   

   
   bioRxiv

2. VENTURA L, Keaser ML, Hernandez-Rojas LG, Shahed M, et al
   Sex-dependent changes in insular cortex connectivity in a rat model of comorbid pain.
   bioRxiv [Preprint]. 2026 Feb 10:2026.02.07.704080.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

3. STURKENBOOM R, Essers BAB, Masclee AAM, Keszthelyi D, et al
   Gender-dependent preferences of medical professionals in treatment choices for irritable bowel syndrome: results from an exploratory study.
   BMC Gastroenterol. 2026 Feb 25. doi: 10.1186/s12876-026-04660.
   PubMed        
   
   

   
   Euroasian J Hepatogastroenterol

4. BEKTAS A
   Non-celiac Gluten Sensitivity: A New Clinical Entity or Growing Controversy?
   Euroasian J Hepatogastroenterol. 2025;15:170-172.
   PubMed         Abstract available
   
   

   
   Foods

5. PAMUEANGMUN P, Kham NNN, Kanpiengjai A, Saenjum C, et al
   Probiotic Potential of Weizmannia coagulans MA42, an Endospore-Forming Probiotic Bacterium Capable of Dietary Fiber Digestion.
   Foods. 2026;15:710.
   PubMed         Abstract available
   
   

   
   Front Immunol

6. QUAN Z, Song W, Huang Q, Wang J, et al
   The effects of different exercise interventions on clinical outcomes of irritable bowel syndrome and their potential mechanisms: a systematic review and network meta-analysis.
   Front Immunol. 2026;17:1730624.
   PubMed         Abstract available
   
   

   
   Front Med (Lausanne)

7. LI Q, Fan M, Gao A, Qin L, et al
   Evaluating the real-world safety of cholestyramine for the treatment of hyperlipidemia: disproportionality analysis of FAERS data.
   Front Med (Lausanne). 2026;13:1765949.
   PubMed         Abstract available
   
   

   
   Fundam Clin Pharmacol

8. ATALAY BR, Yurtseven B, Akbaba E, Ayaz F, et al
   Immunomodulatory Effects of Hyoscine Butylbromide on Mammalian Macrophages.
   Fundam Clin Pharmacol. 2026;40:e70075.
   PubMed         Abstract available
   
   

   
   Int Immunopharmacol

9. ASHAOLU TJ, Suttikhana I
   Probiotic therapeutics: A critical review of mechanisms, clinical efficacy, and the frontier of precision microbiome modulation.
   Int Immunopharmacol. 2026;175:116412.
   PubMed         Abstract available
   
   

   
   Int J Dermatol

10. TALASILA S, Ahmed A, Malick H, Nadir U, et al
    Modestly Increased Incidence of Irritable Bowel Syndrome in Hidradenitis Suppurativa: A Retrospective Cohort Study Using TriNetX.
    Int J Dermatol. 2026 Feb 26. doi: 10.1111/ijd.70357.
    PubMed        
    
    

    
    J Biomater Sci Polym Ed

11. GHOSH D, Sharma R, Katiyar D, Mittal A, et al
    An overview of commercially available polymers for colon-targeted drug delivery systems.
    J Biomater Sci Polym Ed. 2026 Feb 23:1-39. doi: 10.1080/09205063.2026.2628305.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

12. LI X
    Reconsidering Bloating as a Core Endpoint in IBS-C: Commentary on Brenner et al. (2025).
    J Gastroenterol Hepatol. 2026 Feb 26. doi: 10.1111/jgh.70320.
    PubMed        
    
    

    
    J Pediatr Gastroenterol Nutr

13. QUATRALE G, Chirico N, Colecchia L, Stella G, et al
    Prevalence of disorders of gut-brain-interaction in pediatric patients with in-remission inflammatory bowel disease: An Italian multicenter study.
    J Pediatr Gastroenterol Nutr. 2026 Feb 23. doi: 10.1002/jpn3.70386.
    PubMed         Abstract available
    
    

    
    J Tradit Chin Med

14. MI Z, Huaien BU, Dongjun W, Naijin Z, et al
    Efficacy of Tongxie Yaofang compared with pinaverium bromide on irritable bowel syndrome with liver depression and spleen deficiency: a systematic review and Meta-analysis.
    J Tradit Chin Med. 2026;46:14-21.
    PubMed         Abstract available
    
    

    
    Mol Neurobiol

15. TANG Y, He Z, Zhang Q, Liu Y, et al
    Hippocampal Neuronal Ferroptosis Driven by Lipocalin-2 Mediates Comorbid Visceral Pain and Anxiety in Irritable Bowel Syndrome.
    Mol Neurobiol. 2026;63:469.
    PubMed         Abstract available
    
    

    
    Nutrients

16. SEIDITA A, Mansueto P, Pistone M, Soresi M, et al
    Atopy and Other Sensitivities in Non-Celiac Wheat Sensitivity: Is There an Associated Hypersensitivity Background? (dagger).
    Nutrients. 2026;18:609.
    PubMed         Abstract available
    
    
17. INDRIO F, Di Mauro A, Perrone G, Greco A, et al
    Long-Term Efficacy of Limosilactobacillus reuteri DSM17938 in the Prevention of Functional Abdominal Pain Disorders.
    Nutrients. 2026;18:687.
    PubMed         Abstract available
    
    
18. COLECCHIA L, Marasco G, Meacci D, Cremon C, et al
    Nutritional Management of Irritable Bowel Syndrome.
    Nutrients. 2026;18:699.
    PubMed         Abstract available
    
    

    
    Pharmaceutics

19. COSIMATO I, Brescia A, Franci G, Casolaro V, et al
    Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota.
    Pharmaceutics. 2026;18:197.
    PubMed         Abstract available
    
    

    
    Pharmacol Rep

20. PALENCA I, Franzin SB, Pesce M, Sarnelli G, et al
    Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.
    Pharmacol Rep. 2026 Feb 23. doi: 10.1007/s43440-026-00830.
    PubMed        
    
    

    
    Psychother Psychosom

21. XIONG N, Mi Q, Sun Q, Liu Q, et al
    Disrupted Prefrontal Regulation of Social Rejection in Irritable Bowel Syndrome.
    Psychother Psychosom. 2026 Feb 26:1-26. doi: 10.1159/000551116.
    PubMed         Abstract available
    
    

    
    RSC Adv

22. MISHRA AS, Ghosh B, Malliappan SP, Dutta G, et al
    Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.
    RSC Adv. 2026;16:10022-10059.
    PubMed         Abstract available
    
    

    
    Therap Adv Gastroenterol

23. MARASCO G, Meacci D, Sarnelli G, Tosetti C, et al
    Diarrhea management: from pathophysiology to microbiota modulation.
    Therap Adv Gastroenterol. 2026;19:17562848261424324.
    PubMed         Abstract available
    
    

    
    Viruses

24. DE STEFANIS S, Colavita F, Maggi F, Antonioli M, et al
    SARS-CoV-2 Persistence and the Gut Microbiota: New Insights into Long COVID Pathogenesis.
    Viruses. 2026;18:247.
    PubMed         Abstract available
    
    

    
    Zhen Ci Yan Jiu

25. ZHANG HF, Huang R, Jiang F, Li F, et al
    [Clinical study of acupuncture at force-sensitive acupoints in treatment of diarrhea-predominant irritable bowel syndrome].
    Zhen Ci Yan Jiu. 2026;51:233-239.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Irritable Bowel Syndrome is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum